TP53 deletion is not an adverse feature in multiple myeloma treated with total therapy 3.
Contrary to Total Therapy (TT) 2 for multiple myeloma patients, FGFR3- translocation bore no adverse effects on outcome in TT3 with added bortezomib. Del TP53, another poor-risk feature in TT2 and present in 10% of 441 patients treated, was examined for its prognostic consequences in TT3. Not affecting rate or duration of complete response, TP53 haplo-insufficiency also did not compromise, in the 83% with genomically defined low-risk myeloma, survival or event-free survival. FGFR3+ and FGFR3- molecular subgroups fared worse in the presence of del TP53 when applying TT2 but not TT3. Thus, the prognostic implications of del TP53 were protocol-, genome-defined risk- and molecular subgroup-dependent.
Shaughnessy
John D
JD
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
Zhou
Yiming
Y
Haessler
Jeff
J
van Rhee
Frits
F
Anaissie
Elias
E
Nair
Bijay
B
Waheed
Sarah
S
Alsayed
Yazan
Y
Epstein
Joshua
J
Crowley
John
J
Barlogie
Bart
B
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001897:Boronic Acids / Q000008:administration & dosage; D000069286:Bortezomib; D005500:Follow-Up Studies; D017353:Gene Deletion; D006801:Humans; D009101:Multiple Myeloma / Q000188:drug therapy / Q000235:genetics*; D011379:Prognosis; D011719:Pyrazines / Q000008:administration & dosage; D016019:Survival Analysis; D016896:Treatment Outcome; D016159:Tumor Suppressor Protein p53 / Q000235:genetics*
D001897:Boronic Acids; D011719:Pyrazines; C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53; D000069286:Bortezomib
N Engl J Med. 2008 Aug 28;359(9):906-17
18753647
Genes Chromosomes Cancer. 1997 Jun;19(2):124-33
9172003
Blood. 2007 Mar 15;109(6):2276-84
17105813
Blood. 2003 Mar 15;101(6):2377-80
12424198
Cancer Res. 2004 Feb 15;64(4):1546-58
14989251
Br J Haematol. 2008 Mar;140(6):625-34
18302711
Blood. 2004 Jan 1;103(1):20-32
12969978
Leukemia. 2008 Dec;22(12):2247-56
18769451
Blood. 2006 Sep 15;108(6):2020-8
16728703
Cancer Res. 2007 Aug 1;67(15):7395-405
17671210